(Q38071847)

English

Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies

scientific article published on 04 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

0 references

1 reference

Europe PubMed Central

Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

systematic review

1 reference

based on heuristic

inferred from title

Markolf Hanefeld

2

object named as

Markolf Hanefeld

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Andreas Pfützner

6

object named as

Andreas Pfützner

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

author name string

Thomas Forst

1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Stephan Jacob

3

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Guido Moeser

4

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Gero Schwenk

5

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Axel Haupt

7

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

language of work or name

0 references

publication date

4 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Diabetes and Vascular Disease Research

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

302-314

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention--a retrospective nationwide cohort study

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Explaining the decline in early mortality in men and women with type 2 diabetes: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Impact of glycaemic control, hypertension and insulin treatment on general and cause-specific mortality: an Italian population-based cohort of type II (non-insulin-dependent) diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Improved clinical outcomes associated with metformin in patients with diabetes and heart failure

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA)

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Metformin use and mortality among patients with diabetes and atherothrombosis

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Predicting 6-year mortality risk in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Thiazolidinediones and cardiovascular outcomes in older patients with diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with c

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Card

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al.

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Relation between visceral fat and coronary artery disease evaluated by multidetector computed tomography.

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Relationships among age, proinsulin conversion, and beta-cell function in nondiabetic humans

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: an 11-year follow-up of the Hoorn Study

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Sex differences in the association between proinsulin and intact insulin with coronary heart disease in nondiabetic older adults: the Rancho Bernardo Study

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Proinsulin is an independent predictor of the angiographical characteristics of coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Controversies in management of diabetes in patients with coronary heart disease

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Sulphonylurea action revisited: the post-cloning era.

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

The effect of glibenclamide on cutaneous laser-Doppler flux

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis.

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Severe hypoglycemia and risks of vascular events and death

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Continuous glucose monitoring reveals associations of glucose levels with QT interval length

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Hypoglycaemia and cardiac arrhythmias in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1177%2F1479164112465442

21 January 2018

Identifiers

10.1177/1479164112465442

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38071847&oldid=2172330154"